Literature review · Metabolism & weight

Retatrutide

Retatrutide research now includes phase 3 human results as well as earlier phase 2 work. That progress concerns defined investigational preparations, not validation of catalogue products.

By HeartPep · Reviewed · 6 selected source records

Buy from HeartPep.com

Laboratory research only. Not for human or veterinary use.

At a glance

Selected evidence includes phase 2 and 3 obesity trials, a phase 3 knee osteoarthritis report and registry results from a phase 2b kidney function trial.

Identity & scope

Retatrutide is a single peptide with GIP, GLP-1 and glucagon receptor agonist activity. The opaque catalogue label R3ta is not assumed to identify the same material.

Catalogue labels covered: Retatrutide.

What the research shows

  • The phase 2 trial reported dose-related weight changes and gastrointestinal adverse events [1].
  • TRIUMPH-1 provides larger, longer placebo-controlled evidence, including prespecified osteoarthritis and sleep-apnoea subgroup outcomes [2].
  • The 2026 knee osteoarthritis report adds a stand-alone randomized comparison and a fuller account of the previously reported TRIUMPH-1 subgroup [4].
  • Phase 2b registry results did not show a clear difference in the trial’s primary kidney filtration measure [5].

Critical interpretation

The 2026 evidence is broader, but populations remain distinct

Describing retatrutide solely as a phase 2 candidate would omit the phase 3 publications now available. TRIUMPH-1 studied obesity without diabetes, while TRIUMPH-2 included type 2 diabetes and generally background medication. Their weight-change percentages should therefore not be treated as interchangeable expectations or compared as though patients were randomized between these populations. The later trial also reports tolerability findings beyond gastrointestinal events. Its value is a larger, separately defined clinical comparison, rather than a reason to transfer results to a differently formulated commercial research product. [2] [3]

Outcome definitions and analysis choices matter

TRIUMPH-1 combines a main obesity question with prespecified osteoarthritis and sleep-apnoea subgroup questions. Weight and subgroup outcomes do not all use identical strategies for handling treatment interruption, so their effect estimates require the corresponding analysis definition. TRIUMPH-2 explicitly uses a treatment-regimen approach with imputation for missing observations. These features should be examined in protocols and supplements before undertaking a meta-analysis or making comparative claims. None of the trials is a direct head-to-head comparison with semaglutide or tirzepatide, and publication alone does not establish regulatory approval. [2] [3]

Separate the knee pain result from disease modification

The additional independent comparison is TRIUMPH-4. TRIUMPH-1-OA expands the result for a subgroup already reported by Jastreboff and colleagues, so counting those participants twice would exaggerate the amount of evidence. The intention-to-treat sensitivity analysis also favoured retatrutide on pain, with smaller differences. In TRIUMPH-4, any adverse event led to discontinuation in 12.8–18.2% of the active groups versus 4.0% with placebo. The symptom results leave open whether weight loss accounts for the improvement and whether the treatment alters joint structure or the likelihood of surgery. [4] [2]

The prespecified kidney filtration endpoint was inconclusive

The trial detected no clear difference in measured filtration. A secondary comparison of urine albumin-to-creatinine ratio favoured retatrutide, based on 42 participants. The smaller sample and secondary status limit interpretation. Neither result establishes whether retatrutide slows chronic kidney disease over time. [5]

Limitations & uncertainties

  • A trial publication does not establish a current marketing authorization, nor equivalence to any catalogue vial or nasal product.
  • Different analysis strategies for different outcomes require care. Manufacturer funding, missing-data handling and uncommon adverse effects require full-paper appraisal.

Open research questions

  • How do the results replicate across populations, longer follow-up and outcome-specific studies?
  • What do complete protocols, supplementary data and independent analyses add to the abstract-level findings?

Selected papers & source records

Download bibliography
Human studyNamed compoundAbstract / record checked

1. Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial (opens in a new tab)

Jastreboff AM, Kaplan LM, Frías JP, et al. (2023). New England Journal of Medicine. DOI: 10.1056/NEJMoa2301972 (opens in a new tab) · PMID 37366315

Design & population
48-week double-blind randomized placebo-controlled phase 2 trial involving 338 adults.
What the study found
The largest mean weight reduction reported at 48 weeks was 24.2%, versus 2.1% with placebo. Gastrointestinal events and increases in heart rate were reported.
Limits on interpretation
Dose-finding trial, not a comparison with other medicines or evidence for a supplied research formulation. Long-term and rare harms are not settled by this sample.
Human studyNamed compoundAbstract / record checked

2. Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity (opens in a new tab)

Jastreboff AM, Kaplan LM, Davies MJ, et al.; TRIUMPH-1 Investigators (2026). New England Journal of Medicine. DOI: 10.1056/NEJMoa2604169 (opens in a new tab) · PMID 42814954

Design & population
80-week double-blind randomized phase 3 placebo-controlled trial in 2,339 adults with obesity without diabetes.
What the study found
Mean weight change ranged from -17.6% to -25.0% across retatrutide groups, versus -3.9% with placebo. Gastrointestinal events were the most common adverse events.
Limits on interpretation
Defined investigational formulation and selected population. Subgroup outcomes use specified estimands, and the abstract is not a complete safety assessment. No catalogue product was tested.
Human studyNamed compoundAbstract / record checked

3. Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial (opens in a new tab)

Bellido V, le Roux CW, Ekinci EI, et al. (2026). The Lancet. DOI: 10.1016/S0140-6736(26)01861-1 (opens in a new tab) · PMID 42810372

Design & population
80-week randomized placebo-controlled trial in 1,152 adults with obesity or overweight and type 2 diabetes.
What the study found
Average weight reductions favoured retatrutide. Gastrointestinal events, hypotension and dysesthesia were more frequent in active groups, and discontinuation varied by trial group.
Limits on interpretation
Different population from TRIUMPH-1, with background glucose-lowering treatment in most participants. Manufacturer-funded and not a direct comparison against another weight-management medicine.
Human studyNamed compoundFull text consulted

4. Retatrutide Once Weekly in Adults with Knee Osteoarthritis Pain and Obesity (opens in a new tab)

Schnitzer TJ, Hunter DJ, Conaghan PG, et al. (2026). New England Journal of Medicine. DOI: 10.1056/NEJMoa2610676 (opens in a new tab) · PMID 43001755

Design & population
Two double-blind, randomized phase 3 comparisons of subcutaneous retatrutide with placebo in adults with overweight or obesity and painful knee osteoarthritis, without diabetes. TRIUMPH-4 enrolled 445. TRIUMPH-1-OA reports 574 participants already included in TRIUMPH-1.
What the study found
In TRIUMPH-4, placebo-adjusted improvements in pain were 1.61 and 1.83 points on the 0–10 WOMAC scale at week 68 under the primary hybrid analysis. Both trials reported gastrointestinal events and more altered sensations (dysesthesia) with retatrutide.
Limits on interpretation
Sponsor-funded trials in a selected population. The trials did not test structural progression or avoidance of knee replacement. Consulted the journal abstract and the full peer-reviewed accepted manuscript in a university repository.
Human studyNamed compoundBibliographic record checked

5. TRANSCEND-CKD: retatrutide and renal function (NCT05936151) (opens in a new tab)

Eli Lilly and Company (sponsor) (2026). ClinicalTrials.gov registry results.

Design & population
Double-masked, randomized phase 2b trial in 146 adults with overweight or obesity and chronic kidney disease, with or without type 2 diabetes. Registry results first posted 9 November 2026.
What the study found
At 24 weeks, the primary analysis of iohexol-measured kidney filtration included 113 participants. The estimated difference was −1.44 mL/min/1.73 m² (95% CI −9.17 to 6.30, p = 0.714). Serious adverse events were reported in 9 of 73 retatrutide recipients and 6 of 69 placebo recipients.
Limits on interpretation
Sponsor-submitted registry tables. The short follow-up and missing filtration measurements limit conclusions about long-term kidney outcomes. The available journal paper linked in the record describes the design and baseline characteristics.
Human studyNamed compoundAbstract / record checked

6. Retatrutide Once Weekly for Treatment of Obstructive Sleep Apnea (opens in a new tab)

Grunstein RR et al. (2026). New England Journal of Medicine. DOI: 10.1056/NEJMoa2611477 (opens in a new tab) · PMID 42904878

Design & population
Prespecified sleep-apnea analyses within the randomized TRIUMPH-1 and TRIUMPH-2 trials.
What the study found
The report found greater reductions in the apnea–hypopnea index with retatrutide than with placebo in the analyzed groups.
Limits on interpretation
This separate publication uses groups within the parent trials and is not independent replication. It does not establish effects beyond the enrolled populations or validate a catalogue product.

Search & review scope

Targeted PubMed, journal, university repository and ClinicalTrials.gov results check. Also checked newly indexed or previously omitted original abstracts and identifiers.. Checked 20 November 2026.

Reviewed the knee osteoarthritis accepted manuscript and publisher abstract, checked both registration records and read the posted TRANSCEND-CKD results tables. Added selected human study records dated 2026, with study-specific limitations.

Selected outcomes and safety results. Earlier obesity papers are summarised at abstract level. Supplements and individual participant data were outside this review.

Recorded search terms
  • PubMed: retatrutide OR LY3437943, 6–16 November 2026 entry or publication dates
  • PMID 43001755 / DOI 10.1056/NEJMoa2610676
  • ClinicalTrials.gov NCT05931367, NCT05929066 and NCT05936151
  • PMID 42904878 / DOI 10.1056/NEJMoa2611477

Read the collection’s methods and editorial limits. For formal research, assess and cite the original paper.

Cite this review

HeartPep. Retatrutide: literature review. HeartPep literature library. Reviewed 20 November 2026. https://heartpep.com/uk/research/library/retatrutide.

HeartPep is the commercial publisher of this secondary summary. It is not a peer-reviewed primary paper. Cite the original studies for their findings.

Buy from HeartPep.com

Laboratory research only. Not for human or veterinary use.

← All reviews and reference notes